Greg Jones

Greg Jones

Company: Pfizer

Job title: Principal Scientist


Targeting RAF Kinases to Overcome Adaptive Resistance to RAS Targeted Therapies 9:00 am

Clinical and pre-clinical data emphasizes the frequency of on-target and onpathway (ERK-MAPK) adaptive and acquired resistance mechanisms to KRASG12C targeted therapies. CRISPR LoF screens in KRAS-G12C inhibitor resistant cell lines reveal gene subsets whose depletion restores sensitivity to KRASG12C inhibitor treatment. RAF kinases, notably CRAF, was uncovered as one such gene. CRISPR genetic ablation and…Read more

day: Day Two

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.